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Abstract
Accumulation of misfolded neurotoxic Cu, Zn-superoxide dismutase-1 (SOD1) protein found in both familial and
sporadic amyotrophic lateral sclerosis (ALS) is recognized as an important contributing factor of neuronal cell death.
However, little is known about the mechanisms controlling the accumulation and turnover of SOD1 protein.
Puromycin-sensitive aminopeptidase (PSA/NPEPPS) was recently identified as a major peptidase acting on neurotoxic
TAU protein and protecting against TAU-induced neurodegeneration. In addition, recent report implicated PSA/NPEPPS
in the direct removal of neurotoxic polyglutamine repeats. These combined data suggest that PSA/NPEPPS might
represent a novel degradation pathway targeting pathologically aggregating neurotoxic protein substrates including
SOD1. Here, we report that PSA/NPEPPS directly regulates SOD1 protein abundance and clearance via proteolysis. In
addition, PSA/NPEPPS expression is significantly decreased in motor neurons of both SODG93A transgenic mice and
sporadic ALS patients, suggesting its possible contribution to the disease pathogenesis. These results implicate SOD1 as
a new target protein of PSA/NPEPPS and point to the possible neuroprotective role of PSA/NPEPPS in ALS.
Findings
Familial amyotrophic lateral sclerosis (FALS) represents
about 10% of ALS cases. It is most frequently inherited
as an autosomal dominant trait [1]. In about 20% of
FALS patients, at least one type of mutation in Cu, Zn-
superoxide dismutase-1 (SOD1) can be found [2]. The
ubiquitous SOD1 protein converts superoxide radical
anions to oxygen and hydrogen peroxide. More than a
hundred SOD1 gain-of-function mutations have been
identified, which may contribute to increased oxidative
stress, altered copper metabolism, protein aggregation,
excitotoxicity, or altered axonal transport [3]. Several
other genes, including alsin, senataxin, vesicle-associated
membrane protein-associated protein B, angiogenin, and
TAR DNA binding protein, have also been found to be
associated with ALS [4,5]. However, about 90% of ALS
cases have no clear genetic cause, and the condition is
referred to as sporadic amyotrophic lateral sclerosis
(SALS) [4].
One of the hypotheses explaining selective motor neu-
ron degeneration in ALS is the toxicity of intracellular
protein aggregates. One of the major protein aggregates
commonly found in FALS is the misfolded SOD1 protein
[6-8]. Not surprisingly, aggregates of mutated SOD1 pro-
tein are found in neurons and astrocytes of SOD1 trans-
genic animals, including G37R, G85R and G93A models,
and the degree of SOD1 accumulation strongly correlates
with motor neuron dysfunction [9]. Immunohistochemical
studies have also localized these inclusions predominantly
to motor neurons, and in some cases, astrocytes [10].
Wild-type misfolded SOD1 is also found in the spinal cord
extracts of SALS patients and may play a role in the etiol-
ogy of SALS [6,11,12].
Accumulation of abnormally folded proteins and pep-
tides is a key feature of many neurodegenerative diseases,
including Alzheimer’s disease, Huntington’s disease and
ALS [13-16]. The presence of misfolded SOD1 protein in
both familial and sporadic ALS presents a credible
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explanation of motor neuron specific death in ALS
[6,8,11,12,17-19]. Recent work convincingly demonstrated
that wild-type SOD1 and mutant SOD1 share a conforma-
tional epitope prone to oxidation and therefore exert a
strong neurotoxic effect [11,12,20]. These data strongly
support the hypothesis that either mutated or wild-type
SOD1 misfolding contributes to disease pathogenesis in
both familial and sporadic ALS. Recent studies describing
RNAi based allele-specific silencing of mutant SOD1 con-
vincingly demonstrated that lowering the levels of mutant
SOD1 protein produces a significant therapeutic benefit in
SOD1G93A mice [21]. This shows that targeting SOD1 is a
viable and important therapeutic strategy for which identi-
fication and characterization of mechanisms controlling
SOD1 protein degradation would play a central role.
Unfortunately, the causes of SOD1 misfolding/accumula-
tion, and more importantly, the mechanisms of the clear-
ance of pathological aggregates remain unclear, which
may very well be a valid target of novel therapeutic
approaches for ALS.
Recently, we have identified puromycin-sensitive ami-
nopeptidase (PSA, also known as NPEPPS) as a novel
modifier of TAU-induced neurodegeneration with neuro-
protective effects via direct proteolysis of TAU protein
[22,23], which was later confirmed by others [24].
Another recent report implicated PSA as the major pepti-
dase digesting polyglutamine sequences in Huntington’s
disease [25]. In addition, it was recently hypothesized
that neuroprotective effect of PSA/NPEPPS may be
linked to the autophagy system and several other neuro-
toxic targets in vitro, including polyQ-expanded hunting-
tin exon-1, ataxin-3, mutant a-synuclein, and SOD1 [26].
These results suggest that PSA/NPEPPS may represent a
universal neuroprotective mechanism acting on patholo-
gically aggregating neurotoxic proteins substrates, includ-
ing SOD1. However, the questions whether PSA/NPEPPS
is capable of removing SOD1 protein directly through its
proteolytic activity and whether it contributes to the
pathogenesis of familial and sporadic ALS remain
unanswered.
Here, we investigated the role of PSA/NPEPPS in
SOD1 protein clearance in vitro in cell culture and cell-
free systems and evaluated the levels of PSA/NPEPPS in
both human postmortem SALS motor neurons and
murine ALS model tissues.
We first tested whether PSA/NPEPPS overexpression is
able to reduce the abundance of endogenous SOD1 in
human neuroblastoma SH-SY5Y cells. SH-SY5Y cells
were transfected with human PSA/NPEPPS overexpres-
sion vectors, pCMV6-XL-hPSA and then the endogenous
SOD1 was analyzed with Western blot and immunocyto-
chemistry according to standard protocols and previously
published protocols, respectively [27]. The highest trans-
fection peaks for PSA/NPEPPS overexpression was
noticed at 48 and 72 hours (data not shown). While the
analysis of cells at 24 and 48 hours after transfection did
not show any noticeable changes in SOD1 protein
expression (data not shown), cells incubated for 72 hours
post-transfection demonstrated a significant decrease
(nearly 50% reduction; p = 0.0001) of endogenous SOD1
protein (Figure 1A and 1B). We also investigated the
effect of knocking down PSA/NPEPPS expression using
RNA interference (Stealth-RNAi) on SOD1 levels in SH-
SY5Y cells. Reduction of PSA/NPEPPS expression
resulted in an accumulation (~2-fold; p = 0.0075) of
endogenous SOD1 protein within 72 hours (Figure 1A,
B). Our above in vitro experiments in human neuroblas-
toma cell line support the recent observation that PSA/
NPEPPS is a modulator of SOD1 protein abundance in
293A cells [26].
Moreover, we also studied whether overexpression of
SOD1 affects the expression of endogenous PSA/NPEPPS.
In mouse neuroblastoma cell line N1E-115 transfected
with mouse SOD1 overexpression vectors pCMV6-XL-
SOD1, mouse PSA/NPEPPS protein expression was upre-
gulated up to 4-fold (p = 0.0001) (Figure 1C). Thus, it
seems that PSA/NPEPPS expression is directly propor-
tional to the levels of SOD1 protein and the elevation of
SOD1 leads to significant increase in PSA/NPEPPS protein
expression. These observations taken together suggest that
PSA/NPEPPS is indeed a direct endogenous regulator of
SOD1 protein abundance and its expression is controlled
in response to alterations of intracellular SOD1 levels
through a positive feed-back mechanism. A similar regula-
tion of PSA expression has been reported in PC12 cells
that overexpress hungingtin exon 1 containing polyQ
sequences, in which PSA/NPEPPS expression is highly
induced [28]. These results suggest that there may be a
feed-back self-protective mechanism in cells by which
PSA/NPEPPS expression is regulated in response to the
abundance of aggregated toxic proteins. This further
implies the important physiological neuroprotective role
of PSA/NPEPPS.
Using human neuroblastoma SH-SY5Y cells we demon-
strated a strong linkage of PSA/NPEPPS to SOD1 accu-
mulation/clearance (Figure 1A and 1B). This effect may be
mediated by direct interaction of PSA/NPEPPS with
SOD1 resulting in SOD1 protein digestion similar to PSA/
NPEPPS interaction with TAU-protein [22,23]. However,
it is plausible that PSA/NPEPPS has no direct interaction
with SOD1, and acts via cleavage of another intermediary,
such as the autophagy system [26] or ptoteosome system
[25]. Our recent studies of hPSA transgenic mice overex-
pressing human PSA/NPEPPS at nearly 3-fold revealed
that it has no significant effect on either autophagy or pro-
teosome degradation system [29]. Nevertheless, to test the
hypothesis that human PSA/NPEPPS can act directly on
human SOD1 two types of experiments were performed
Ren et al. Molecular Neurodegeneration 2011, 6:29
http://www.molecularneurodegeneration.com/content/6/1/29
Page 2 of 7
in the cell-free system using purified SOD1 and PSA/
NPEPPS proteins.
First, we prepared post-microsomal protein extracts
(S3) from cultured SH-SY5Y cells transfected with PSA/
NPEPPS overexpression vectors, PSA/NPEPPS-specific
RNAi, and corresponding controls, as described pre-
viously [30]. Co-incubation of post-microsomal fractions
with purified human SOD1 was carried out at 37°C for
one, two and four hours in the Bicine buffer, pH 7.0 with
0.2 mM DTT. One microgram of SOD1 highly purified
Figure 1 In vitro studies in neuroblastoma cell lines demonstrate co-regulation of PSA/NPEPPS and SOD1. A. Western blot analysis
shows decrease of endogenous SOD1 in response to PSA/NPEPPS overexpression (PSA↑) and accumulation of SOD1 in response to PSA/NPEPPS
inhibition (PSA↓) with Stealth-RNAi in human SH-SY5Y neuroblastoma cell line. B. Representative immunocytochemistry demonstrates a notable
decrease (top) and a rapid accumulation (bottom) of SOD1 protein (green) in response to PSA/NPEPPS overexpression (PSA↑; top; red) and PSA/
NPEPPS inhibition (PSA↓; bottom), respectively, in SH-SY5Y cells. The middle image represents normal control. PSA/NPEPPS is red, SOD1 is green,
and the nucleus is blue as stained with DAPI nuclear marker. Scale bar 20 μm. C. PSA/NPEPPS expression demonstrated by Western blot is up-
regulated in response to SOD1 overexpression in mouse N1E-115 neuroblastoma cell line. Because mouse SOD1 overexpression construct was
used, we utilized mouse neuroblastoma cell line to avoid possible side effects of heterologous expression of a mouse protein in a human cell
line. For each comparison, three independent experiments were performed (n = 3) with at least three independent replicates in each
experiment. Representative Western blot and immunocytochemistry images are shown. Error bars represent standard deviations.
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from human erythrocytes (Sigma-Aldrich, MO) was co-
incubated with 25 μg of S3 protein extracts isolated from
nontransfected cells (control), cells transfected with PSA/
NPEPPS overexpression vectors (PSA↑), and cells trans-
fected with Stealth-RNAi (Invitrogen, CA) specific for
human PSA/NPEPPS (PSA↓). The reactions were termi-
nated by the addition of Laemmli SDS sample buffer and
boiling for 5 min. Subsequently SOD1 proteins that
remained in the reaction mixtures were analyzed by Wes-
tern blot with SOD1 antibodies (MBL Intl, MO). While
one hour incubation did not produce any noticeable
effect on SOD1, two hours incubation resulted in a sig-
nificantly increased SOD1 degradation rate (2-fold, p =
0.04) with the post-microsomal extracts containing ele-
vated PSA/NPEPPS compared to using the post-microso-
mal extracts from control cells. Prolonged incubation for
up to 4 hours resulted in the degradation of SOD1 in
both experimental and control samples due to the pre-
sence of other proteases in the post-microsomal protein
extracts. On the contrary, with post-microsomal protein
extracts from PSA/NPEPPS-RNAi treated cells with
knocked down PSA/NPEPPS, the rates of SOD1 degrada-
tion were significantly reduced (p < 0.01) at all time
points in comparison to using protein extracts with ele-
vated PSA/NPEPPS and controls (Figure 2A). The
decrease in SOD1 degradation rate ranged from 1.24-fold
(p = 0.04) after 1 hour to 9.7-fold (p < 0.01) after 4 hours
of co-incubation. Experimental data presented above
using the purified SOD1 and post-microsomal protein
fractions that lack the autophagy system activity indicate
that without the involvement of autophagy system
PSA/NPEPPS is still capable of hydrolyzing SOD1
independently.
Although post-microsomal protein fractions are free of
autophagosomal vesicles, other cytoplasmic peptidases
may contribute to SOD1 degradation process [31]. To
further confirm that PSA/NPEPPS indeed acts on SOD1
protein directly and is capable of degrading it, we incu-
bated purified human SOD1 with well-purified PSA/
NPEPPS in a cell-free system. PSA/NPEPPS was purified
from brains of adult male Sprague-Dawley rats (250-300
g) and its activity was measured with 20 μM Leu bNA
(Leu-naphthylamide) as described previously [32]. For
PSA-SOD1 incubation experiments, digestion of highly
purified human SOD1 (Sigma-Aldrich, MO) was carried
out at 37°C for 6 hrs in 50 mM Bicine buffer, pH 7.0,
containing 0.2 mM DTT, at a molar ratio of 1:6 (PSA:
SOD1). The reaction was terminated by 5% perchloroa-
cetic acid and analyzed by Western blot as described
above. After 6 hours of incubation, full-length SOD1
was greatly diminished of its original amount (about
80% decrease, p = 0.004) (Figure 2B). These results
further strengthen the hypothesis of PSA/NPEPPS-speci-
fic SOD1 degradation through its direct proteolytic
activity similar to the effect of PSA/NPEPPS on TAU-
protein [22,23]. Moreover, our studies with post-micro-
somal protein fractions showed that such protein frac-
tions even from cells that lack PSA/NPEPPS expression
are also capable of digesting SOD1 protein at a low rate,
which suggests that there may be other unknown
Figure 2 Experiments in the cell-free system by Western blot analysis confirm direct interaction of PSA/NPEPPS and SOD1. A. Purified
human SOD1 was incubated with post-microsomal protein fractions of SH-SY5Y cells transfected with PSA/NPEPPS overexpressing vector (PSA↑),
blank vector (Cntr) or Stealth-RNAi specific for hPSA/NPEPPS (PSA↓); and the exhibited SOD1 levels are reversely proportional to the levels of
PSA/NPEPPS protein. Independent experimental triplicates are shown. B. Incubation of purified human SOD1 with purified rat PSA/NPEPPS for 6
hours demonstrates up to 80% proteolysis of human SOD1. Controls contained human SOD1 only. The gel bands in B demonstrate the results
from two independent co-incubation experiments. Only representative images are shown. Error bars represent standard deviations.
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PSA-independent mechanisms responsible for SOD1
hydrolysis, which remain to be verified in the future.
Based on observations made by us and by others [26],
PSA/NPEPPS may regulate SOD1 degradation through
both direct (i.e. its proteolytic activity) and indirect
(such as autophagy system involved) mechanisms. Our
findings indicate that SOD1 protein may be removed
directly through the increased activity of PSA/NPEPPS,
and implicate this enzyme as an important modulator of
SOD1-induced motor neuron degeneration in ALS.
Even though it seems that SOD1 overexpression in
vitro may trigger PSA/NPEPPS upregulation (Figure
1C), the response of PSA/NPEPPS to the expression of
mutated and dysfunctional SOD1 found in FALS is
unknown. To investigate the effect of long term consti-
tutive overexpression of mutated SOD1 in vivo, we first
studied the expression levels of PSA/NPEPPS in
SOD1G93A transgenic mice and control littermates [33].
SOD1G93A mice, strain B6SJL-Tg (SOD1-G93A)1Gur,
were obtained from The Jackson Laboratory (Bar Har-
bor, ME). This strain expresses the transgene under the
control of the endogenous human promoter [34].
Female SOD1G93A transgenic and non-transgenic control
littermates were sacrificed at the age before the onset of
the known disease pathology (2 months) and during the
symptomatic stage (4 months). Western blot analysis
using antibodies against PSA/NPEPPS was performed
with the protein lysates extracted from the spinal cords
of each group of animals. All animal protocols were in
accordance with the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the Los
Angeles Biomedical Research Institute and Nathan S.
Kline Institute for Psychiatric Research animal studies
committees. These experiments demonstrated significant
reduction of PSA/NPEPPS in the tissues of SOD1G93A
transgenic mice at both ages tested (p = 0.003 and p =
0.001 respectively) compared to control mice, suggesting
that contrary to the short-term effect in vitro prolonged
accumulation of mutated SOD1 negatively regulates
PSA/NPEPPS expression in vivo (Figure 3A and 3B).
Although the presence of misfolded SOD1 in the
motor neurons of sporadic ALS patients is still a
debated topic evidenced by several contradicting reports
[6,8,11,12,17-19,35,36], recently published data points to
the importance of SOD1 in the pathogenesis of the
sporadic disease [11]. It was demonstrated that oxidized
wild-type SOD1 shares similar structural and neurotoxic
features with mutated SOD1. It appears that SOD1 oxi-
dation process leads to specific conformational changes
in SOD1 creating an epitope identical to mutated and
neurotoxic SOD1 [11]. In over 50% of SALS patients
such aberrant wild-type SOD1 are detected, and SOD1
extracted from tissue samples of SALS patients, but not
SOD1 from healthy controls, inhibited axonal transport,
pointing to its strong neurodegenerative potential [11].
These results suggest that abnormal conformations of
oxidized wild-type SOD1 could indeed mediate motor
neuron toxicity in SALS similar to the role of mutated
SOD1 in FALS [37].
We then studied whether PSA/NPEPPS expression was
altered in SALS patients. Post-mortem paraffin-embedded
clinically relevant brain and spinal cord tissue blocks from
SALS patients (n = 19) and normal controls (n = 6) were
provided by the UCLA Department of Pathology and the
National Neurological AIDS BANK (NNAB), and used for
tissue microarray (TMA) construction at the UCLA Tissue
Array core facility (http://www.genetics.ucla.edu/tissuear-
ray) as described previously [38]. Estimation of PSA/
NPEPPS expression was performed in spinal cord anterior
horn motor neurons of SALS and control subjects. Briefly,
for the estimation of relative PSA/NPEPPS expression, the
total number of PSA/NPEPPS positive motor neurons was
divided by the total number of NeuN positive motor neu-
rons to derive the PSA expression index (PEI) for a given
tissue core. Then, the average PEI for each tissue type and
individual was calculated and used to derive the mean PEI
for SALS and control subjects. The significance was esti-
mated based on a Student’s t-test (P < 0.01). The following
primary antibodies were used: mouse monoclonal anti-
neuronal nuclei (NeuN; 1:100; Chemicon) and goat poly-
clonal anti-PSA (1:1000, Millipore). This high-throughput
immunohistochemical analysis of TMA showed a signifi-
cant decrease of PSA/NPEPPS protein expression in the
SALS motor neurons (p = 0.0013, Figure 3C and 3D). For
the first time, we demonstrated that decreased expression
of PSA/NPEPPS may be a novel contributory factor to the
pathogenesis of ALS, which leads to the impaired clear-
ance of accumulated SOD1.
Our in vitro results with murine neuroblastoma cell
line overexpressing SOD1 demonstrated an increase in
PSA/NPEPPS protein expression (Figure 1C). However,
the evidence in vivo show that the levels of PSA/
NPEPPS protein are dramatically decreased in the trans-
genic mice overexpressing mutated (G93A) form of
human SOD1 and in postmortem spinal cord tissues,
more specifically motor neurons, of SALS patients (Fig-
ure 3). Two possible mechanisms may explain these
conflicting observations in vitro and in vivo: 1. the rapid
upregulation of PSA/NPEPPS is just the early-response
to elevated intracellular SOD1; however, the prolonged
and constitutive elevation of SOD1 eventually leads to
the decreased expression of PSA/NPEPPS; 2. In SALS
disease, the physiological feed-back regulatory mechan-
ism of PSA/NPEPPS expression in response to SOD1
levels is impaired. The latter may represent a novel
angle of view of ALS pathogenesis. Future studies of the
interaction of PSA/NPEPPS with SOD1 would be prere-
quisite to understand its biological mechanisms. In
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particular, the cross between recently developed hPSA
transgenic mice [29] and SOD1G93A mice [33] with sub-
sequent analysis of double transgenic progeny in respect
to SOD1G93A protein accumulation would be valuable.
Further cell free co-incubation experiments using
mutated forms of SOD1 would provide additional infor-
mation on the specificity of interaction with PSA/
NPEPPS. These and other experiments would shed new
light on the role of PSA/NPEPPS in the pathogenesis of
ALS and may provide novel therapeutic and diagnostic
approaches for ALS.
In summary, we present the first evidence that PSA/
NPEPPS is a major protease to directly digest SOD1,
which may be analogous to its role in TAU-induced
neurodegeneration [22-24]. More importantly, its
expression is attenuated in both murine ALS model and
SALS patients, which suggests its potential contribution
to ALS pathogenesis. However, additional functional
and etiological studies are needed to fully evaluate the
role of PSA/NPEPPS in ALS and its possible use as a
therapeutic target facilitating SOD1 protein clearance.
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Figure 3 PSA/NPEPPS is significantly decreased in both SOD1G93A transgenic mice and motor neurons of postmortem SALS patients.
A, B. PSA/NPEPPS protein expression analyzed with Western blot is significantly decreased in the spinal cord of 2 months old (2 m) adult
presymptomatic (n = 4) and 4 months old (4 m) symptomatic (n = 4) SOD1G93A transgenic mice compared to the corresponding littermate 2 (n
= 4) and 4 (n = 4) months old wild-type mice. C, D. A high-throughput immunohistochemical analysis using SALS tissue microarray reveals a
significant decrease of PSA/NPEPPS-positive anterior horn motor neurons in SALS patients (n = 19) compared to healthy controls (n = 6). C.
Representative spinal cord anterior horn tissue cores from SALS and control subjects show that PSA/NPEPPS protein expression is reduced in
SALS motor neurons. Scale bar 20 μm. D. Bar graphs summarizing the findings from SALS tissue microarray show significant decrease of PSA/
NPEPPS in SALS motor neurons. On average, each SALS (n = 19) and control (n = 6) subject was represented by ten spinal cord anterior horn
tissue cores [38]. Error bars represent standard deviations.
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